Vision Medicines, Case Western enter licensing agreement for VM200 for Stargardt disease

Vision Medicines has entered into an exclusive worldwide licensing agreement with Case Western Reserve University for VM200, an oral small molecule drug candidate for the treatment of Stargardt disease, according to a press release. “We are enthusiastic about the potential for VM200 and have initiated investigational new drug application-enabling studies to advance VM200 into a phase 1/2 program for Stargardt disease in 2016,” Chris Varma, PhD, chairman and CEO of Vision Medicines, said in the release.